Background: Treating HFpEF (heart failure with preserved ejection fraction) is complex due to its diverse origins, leaving many patients with limited options. While diuretics offer symptom relief, most therapies don’t markedly improve outcomes. SGLT2 inhibitors, particularly Dapagliflozin, show potential in reducing cardiovascular events. Yet, guidelines for HFpEF and HFmrEF are vague regarding SGLT2 use. This [...]